Provider Network Models
Expert articles and analysis related to provider network models.
AI Summary — Last 24 Hours
Independent physician networks face renewed pressure as payer payment delays threaten cash flow and destabilize practices that many ACOs and risk-bearing groups rely on for access, attribution, and longitudinal care management; the near-term VBC implication is that network adequacy and physician alignment may hinge as much on claims operations and working-capital support as on shared-savings design (Fierce Healthcare). Separately, pressure to redesign value-based contracts for high-cost therapies is intensifying as manufacturers, payers, and providers look for outcomes-based arrangements that can manage specialty-drug affordability without shifting unsustainable risk onto delivery systems.
Related Articles
Trump proposes tariffs on generic pharmaceuticals -- what companies should know
Trump proposes tariffs on generic pharmaceuticals -- what companies should know PwC
How CVS Caremark builds the next era of pharmacy benefits
How CVS Caremark builds the next era of pharmacy benefits Fierce Healthcare
Trump proposes tariffs on generic pharmaceuticals -- what companies should know
Trump proposes tariffs on generic pharmaceuticals -- what companies should know PwC
Reimagining Value-Based Contracts for High-Cost Therapies
MRD-Guided Maintenance and the Question of When to Stop
Tec-Dara Cuts Death Risk 78% Without Raising Fatal Toxicity
Revenue Growth Could Be A Game Changer For CareDx Stock (CDNA) - simplywall.st
Revenue Growth Could Be A Game Changer For CareDx Stock (CDNA) simplywall.st
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval
The FDA approved AbbVie’s next-generation therapy for Parkinson’s disease, tavapadon, a dopamine agonist that's expected to provide the symptom relief of its predecessors but with fewer side effects. ...